Research progress on the relationship between Alzheimer's disease and related cognitive disorders and presenilin 2 gene

doi:10.11817/j.issn.1673-9248.2023.03.017

Abstract

Abstract:

Alzheimer's disease (AD) and related cognitive disorders, such as frontotemporal lobe dementia, Lewy body dementia, Parkinson's disease dementia, and posterior cerebral cortex atrophy, belong to neurodegenerative changes which are irreversible. They are global problems that cause cognitive impairment in young and elderly patients, especially early cognitive impairment. The presenilin 2 (PS2) gene is closely related to the occurrence and development of such diseases, and its probability of gene mutation is relatively rare, which is easy to be ignored by patients and clinicians. Therefore, this article describes the definition of AD and related cognitive disorders and the progress of research on the relationship between AD and PS2 gene, to improve the awareness and understanding of clinicians and the public on such diseases, and do early prevention and intervention in time.

Key words: Alzheimer's disease, Dementia, Cognitive disorder, Presenilin 2 gene

Yu Xia, Han Liu, Rui Zhu. Research progress on the relationship between Alzheimer's disease and related cognitive disorders and presenilin 2 gene[J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 290-293.

/ / Recommend

Add to citation manager EndNote|Ris|BibTeX

URL: https://zhnxgbzz.cma-cmc.com.cn/EN/10.11817/j.issn.1673-9248.2023.03.017

https://zhnxgbzz.cma-cmc.com.cn/EN/Y2023/V17/I03/290

References 44

1	Bekris LM, Yu CE, Bird TD, et al. Genetics of Alzheimer disease [J]. J Geriatr Psychiatry Neurol, 2010, 23(4): 213-227.
2	Chan D, Suk HJ, Jackson BL, et al. Gamma frequency sensory stimulation in mild probable Alzheimer's dementia patients: Results of feasibility and pilot studies [J]. PLoS One, 2022, 17(12): e0278412.
3	Mintun MA, Lo AC, Duggan Evans C, et al. Donanemab in early Alzheimer's disease [J]. N Engl J Med, 2021, 384(18): 1691-1704.
4	Swanson CJ, Zhang Y, Dhadda S, et al. A randomized, double-blind, phase 2b proof-of-concept clinical trial in early Alzheimer's disease with lecanemab, an anti-Aβ protofibril antibody [J]. J Alzheimers Dis, 2021, 13(1): 80.
5	Munoz-Bermejo L, Gonzalez-Becerra MJ, Barrios-Fernandez S, et al. Cost-effectiveness of the comprehensive interdisciplinary program-care in informal caregivers of people with Alzheimer's disease [J]. Int J Environ Res Public Health, 2022, 19(22): 15243.
6	Diehl J, Ernst J, Krapp S, et al. Misdemeanor in frontotemporal dementia [J]. Fortschr Neurol Psychiatr, 2006, 74(4): 203-210.
7	Hughes LE, Rittman T, Regenthal R, et al. Improving response inhibition systems in frontotemporal dementia with citalopram [J]. Brain, 2015, 138(Pt 7): 1961-1975.
8	Phan K, He Y, Pickford R, et al. Uncovering pathophysiological changes in frontotemporal dementia using serum lipids [J]. Sci Rep, 2020, 10(1): 3640.
9	Staffaroni AM, Ljubenkov PA, Kornak J, et al. Longitudinal multimodal imaging and clinical endpoints for frontotemporal dementia clinical trials [J]. Brain, 2019, 142(2): 443-459.
10	O'Connor CM, Clemson L, Brodaty H, et al. The tailored activity program (TAP) to address behavioral disturbances in frontotemporal dementia: a feasibility and pilot study [J]. Disabil Rehabil Assist Technol, 2019, 41(3): 299-310.
11	Silva MC, Ferguson FM, Cai Q, et al. Targeted degradation of aberrant tau in frontotemporal dementia patient-derived neuronal cell models [J]. Elife, 2019, 8: e45457.
12	Lester E, Ooi FK, Bakkar N, et al. Tau aggregates are RNA-protein assemblies that mislocalize multiple nuclear speckle components [J]. Neuron, 2021, 109(10): 1675-1691, e1679.
13	Benson DF, Davis RJ, Snyder BD. Posterior cortical atrophy[J].Arch Neurol, 1988,45(7):789-93.
14	Fedeli C, Filadi R, Rossi A, et al. PSEN2 (presenilin 2) mutants linked to familial Alzheimer disease impair autophagy by altering Ca²⁺ homeostasis [J]. Autophagy, 2019, 15(12): 2044-2062.
15	Arber C, Lovejoy C, Harris L, et al. Familial Alzheimer's disease mutations in PSEN1 lead to premature human stem cell neurogenesis [J]. Cell Rep, 2021, 34(2): 108615.
16	Stanga S, Vrancx C, Tasiaux B, et al. Specificity of presenilin-1- and presenilin-2-dependent gamma-secretases towards substrate processing [J]. J Cell Mol Med, 2018, 22(2): 823-833.
17	Pendin D, Fasolato C, Basso E, et al. Familial Alzheimer's disease presenilin-2 mutants affect Ca²⁺ homeostasis and brain network excitability [J]. Aging Clin Exp Res, 2021, 33(6): 1705-1708.
18	Hu C, Xu J, Zeng L, et al. Pen-2 and presenilin are sufficient to catalyze notch processing [J]. J Alzheimers Dis, 2017, 56(4): 1263-1269.
19	Duan Y, Ye T, Qu Z, et al. Brain-wide Cas9-mediated cleavage of a gene causing familial Alzheimer's disease alleviates amyloid-related pathologies in mice [J]. Nat Biomed Eng, 2022, 6(2): 168-180.
20	Zampese E, Fasolato C, Kipanyula MJ, et al. Presenilin 2 modulates endoplasmic reticulum (ER)-mitochondria interactions and Ca²⁺ cross-talk [J]. Proc Natl Acad Sci U S A, 2011, 108(7): 2777-2782.
21	Xiao X, Liu H, Liu X, et al. APP, PSEN1, and PSEN2 Variants in Alzheimer's disease: systematic re-evaluation according to ACMG guidelines [J]. Front Aging Neurosci, 2021, 13: 695808.
22	Kwart D, Gregg A, Scheckel C, et al. A large panel of isogenic APP and PSEN1 mutant human iPSC neurons reveals shared endosomal abnormalities mediated by APP beta-CTFs, not Abeta [J]. Neuron, 2019, 104(5): 1022.
23	Youn YC, Bagyinszky E, Kim H, et al. Probable novel PSEN2 Val214Leu mutation in Alzheimer's disease supported by structural prediction [J]. BMC neurology, 2014, 14: 105.
24	Ayodele T, Rogaeva E, Kurup JT, et al. Early-onset Alzheimer's disease: what is missing in research [J]. Curr Neurol Neurosci Rep, 2021, 21(2): 4.
25	Lohmann E, Guerreiro RJ, Erginel-Unaltuna N, et al. Identification of PSEN1 and PSEN2 gene mutations and variants in Turkish dementia patients [J]. Neurobiol Aging, 2012, 33(8): 1850 e1817-1827.
26	Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure [J]. Am J Hum Genet, 2006, 79(6): 1030-1039.
27	Guven G, Samanci B, Gulec C, et al. A novel PSEN2 p.Ser175Phe variant in a family with Alzheimer's disease [J]. Neurol Sci, 2021, 42(6): 2497-2504.
28	Li D, Parks SB, Kushner JD, et al. Mutations of presenilin genes in dilated cardiomyopathy and heart failure [J]. Am J Hum Genet, 2006, 79(6): 1030-9
29	Shi Z, Wang Y, Liu S, et al. Clinical and neuroimaging characterization of Chinese dementia patients with PSEN1 and PSEN2 mutations [J]. Dement Geriatr Cogn Disord, 2015, 39(1-2): 32-40.
30	Bernardi L, Tomaino C, Anfossi M, et al. Novel PSEN1 and PGRN mutations in early-onset familial frontotemporal dementia [J]. Neurobiol Aging, 2009, 30(11): 1825-1833.
31	Nacmias B, Piaceri I, Bagnoli S, et al. Genetics of Alzheimer's disease and frontotemporal dementia [J]. Curr Mol Med, 2014, 14(8): 993-1000.
32	Hsu JL, Lin CH, Chen PL, et al. Genetic study of young-onset dementia using targeted gene panel sequencing in Taiwan [J]. Am J Med Genet B Neuropsychiatr Genet, 2021, 186(2): 67-76.
33	Gallo M, Tomaino C, Puccio G, et al. Novel MAPT Val75Ala mutation and PSEN2 Arg62Hys in two siblings with frontotemporal dementia [J]. Neurol Sci, 2010, 31(1): 65-70.
34	Meeus B, Verstraeten A, Crosiers D, et al. DLB and PDD: a role for mutations in dementia and Parkinson disease genes [J]. Neurobiol Aging, 2012, 33(3): 629 e625-629 e618.
35	Kwok JB, Loy CT, Dobson-Stone C, et al. The complex relationship between genotype, pathology and phenotype in familial dementia [J]. Neurobiol Dis, 2020, 145: 105082.
36	Miyamoto M, Miyamoto T. Montreal cognitive assessment predicts the short-term risk of Lewy body disease in isolated REM sleep behavior disorder with reduced MIBG scintigraphy [J]. Mov Disord Clin Pract, 2022, 10(1): 32-41.
37	Bekris LM, Tsuang DW, Peskind ER, et al. Cerebrospinal fluid Aβ 42 levels and APP processing pathway genes in Parkinson's disease [J]. Mov Disord, 2015, 30(7): 936-944.
38	Zeng Q, Pan H, Zhao Y, et al. Evaluation of common and rare variants of Alzheimer's disease-causal genes in Parkinson's disease [J]. Parkinsonism Relat Disord, 2022, 97: 8-14.
39	Perrone F, Cacace R, Van Mossevelde S, et al. Genetic screening in early-onset dementia patients with unclear phenotype: relevance for clinical diagnosis [J]. Neurobiol Aging, 2018, 69: 292.e297-e214.
40	Lange J, Lunde KA, Sletten C, et al. Association of a BACE1 gene polymorphism with Parkinson's disease in a norwegian population [J]. Parkinsons Dis, 2015, 2015: 973298.
41	Li XY, Cui Y, Jing D, et al. Novel PSEN1 and PSEN2 mutations identified in sporadic early-onset Alzheimer disease and posterior cortical atrophy [J]. Alzheimer Dis Assoc Disord, 2021, 35(3): 208-213.
42	Carrasquillo MM, Barber I, Lincoln SJ, et al. Evaluating pathogenic dementia variants in posterior cortical atrophy [J]. Neurobiol Aging, 2016, 37: 38-44.
43	Tremolizzo L, Susani E, Mapelli C, et al. First report of PSEN2 mutation presenting as posterior cortical atrophy [J]. Alzheimer Dis Assoc Disord, 2015, 29(3): 249-251.
44	Luzzis S, Fioric C, Ranaldi V, et al. Allochiria for spatial landmarks as the presenting feature of posterior cortical atrophy [J]. Cortex, 2022, 157: 274-287.

[1]	Shenghua Lu, Baiyun Liu. Research progress in functional evaluation of patients with post-traumatic hydrocephalus [J]. Chinese Journal of Neurotraumatic Surgery(Electronic Edition), 2022, 08(03): 178-182.
[2]	Xinxin Zhao. Changes of peripheral blood helper T cells in elderly patients with vascular dementia and their clinical significance [J]. Chinese Journal of Brain Diseases and Rehabilitation(Electronic Edition), 2022, 12(02): 90-95.
[3]	Yaoyao Wang, Hongxia Yu, Hongyu Wang. Vascular health management and prevention of dementia and cognitive impairment [J]. Chinese Journal of Clinicians(Electronic Edition), 2022, 16(08): 792-795.
[4]	Fangzhou Zuo, Xiaoen Mo, Shasha Xu. Quetiapine versus olanzapine for treatment of patients with dementia related organic brain disorders: therapeutic effects and impact on internal environment indicators [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(08): 631-636.
[5]	Hao Wang, Hailong Zhao, Xiangqi Tian, Xiuhua Li. Research progress on effect of transcranial magnetic stimulation on Parkinson's disease [J]. Chinese Journal of Clinicians(Electronic Edition), 2021, 15(04): 298-301.
[6]	Xiaoqin Yan, Chongxin Wang. Clinical research progress of acupuncture in treating vascular dementia [J]. Chinese Journal of Acupuncture and Moxibustion(Electronic Edition), 2020, 09(03): 102-104.
[7]	Biyan Jiang, Caixia Liu, Shulan Yang, Weimin Lou, Lingyan Chen, Chunying Chen. Construction of group activity program for senile dementia [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2023, 10(02): 37-43.
[8]	Liying Zhuang, Qilun Lai, Lu Liu, Yue Lou, Shanhu Xu, Yu Jin, Xiaoli Liu. The predictive value of Framingham risk score for mild cognitive impairment progress to dementia in middle-aged and elderly patients [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2021, 08(03): 20-23.
[9]	Shulan Yang, Caixia Liu. Co-word cluster analysis of nursing research on dementia [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(03): 36-40.
[10]	ShiMing Li, ZaiFang Chen, Wei Feng, ZiJuan Zhang, Yue Wu, QuePing Yang. Prevalence of dementia in the elderly in China: A systematic review and Meta analysis [J]. Chinese Journal of Geriatrics Research(Electronic Edition), 2020, 07(03): 29-35.
[11]	Dingding Zhang, Jiangxia Zhang, Ning Su, Yun Xu, Kai Wang, Yuming Xu, Zhenzhong Li, Bo Hu, Lihua Wang, Bo Wu, Lan Chu, Yinzhou Wang, Hong Jiang, Zhengqi Lu, Jian Wu, Xiangmin Fan, Fei Han, Ming Yao, Lixin Zhou, Jun Ni, Feng Tian, Jing Yuan, Yicheng Zhu. The normative data of digital cognitive tests among cognitively normal Chinese adults: a national multi-center clinical research [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 179-199.
[12]	Xiaohong Huang, Ning Su, Yicheng Zhu. Review of research progress on the relationship between gait and adverse events based on community cohort [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2023, 17(03): 271-274.
[13]	Ruomeng Qin, Caimei Luo, Mengchun Li, Hui Zhao, Feng Bai, Yun Xu. The cognitive characteristics and assessment scales for the illiteracy [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2021, 15(06): 386-390.
[14]	Yu Tian, Yilong Wang. The role of glymphatic system in cerebral small vessel disease [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2021, 15(04): 200-204.
[15]	Ran Huo, Ying Liu, Haibo Wu, Huimin Xu, Tao Wang, Huishu Yuan. The advance of the mechanism of cognitive impairment in patients with carotid stenosis and the effects of carotid revascularization on cognitive function [J]. Chinese Journal of Cerebrovascular Diseases(Electronic Edition), 2020, 14(04): 194-198.

Please choose a citation manager

Content to export